Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, influence a broad array of pathogenic microorganisms. Previous studies reported that mevastatin inhibited Plasmodium falciparum growth in vitro, but the activity of other statins against P. falciparum remained to be explored. This study assessed the in vitro susceptibilities of chloroquine-susceptible (3D7, D6, IMT031) and chloroquine-resistant (W2, Bre1, FCR3) P. falciparum strains to various statins (simvastatin, simvastatin sodium salt, pravastatin sodium salt, lovastatin, fluvastatin sodium salt, mevastatin, mevastatin sodium salt, atorvastatin calcium salt) using the isotopic microdrug susceptibility test. Results showed that atorvastatin calcium salt was 10-fold more active against P. falciparum than other statins, with 50% inhibitory concentrations (IC50) ranging from 4.8 to 11.8 μM and 90% inhibitory concentrations (IC90) from 14.8 to 39 μM. Its activity was independent of chloroquine resistance status. Simvastatin, fluvastatin, and lovastatin in their salt forms exhibited higher activity than their lactone forms, while pravastatin and mevastatin salts were inactive (IC50 > 200 μM). Structural differences between atorvastatin and other statins may account for its superior activity. Although the IC50 of atorvastatin for P. falciparum exceeds reported steady-state plasma concentrations, it may be below toxic levels. In conclusion, atorvastatin is a promising candidate for further investigations into the use of statins in malaria treatment.